Declared Dividend • Jun 01
Dividend increased to CN¥0.18 Dividend of CN¥0.18 is 80% higher than last year. Ex-date: 5th June 2026 Payment date: 5th June 2026 Dividend yield will be 0.9%, which is lower than the industry average of 2.2%. Sustainability & Growth Dividend is covered by earnings (44% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 21% per year over the past 9 years. However, payments have been volatile during that time. EPS is expected to grow by 138% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • May 30
SonoScape Medical Corp. Announces Implementation of Final Profit Distribution Plan on A Shares for 2025, Payable on 05 June 2026 SonoScape Medical Corp. announced the implementation of final profit distribution plan on A shares for 2025: Cash dividend (tax included) of CNY 1.80000000 per 10 shares. Record date: 04 June 2026 with Ex-date: 05 June 2026. Payment date: 05 June 2026. Buy Or Sell Opportunity • May 27
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 21% to CN¥21.16. The fair value is estimated to be CN¥26.50, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.4% over the last 3 years. Earnings per share has declined by 56%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 163% in the next 2 years. Reported Earnings • Apr 17
Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2025 results: EPS: CN¥0.46 (up from CN¥0.33 in FY 2024). Revenue: CN¥2.31b (up 15% from FY 2024). Net income: CN¥197.3m (up 39% from FY 2024). Profit margin: 8.5% (up from 7.1% in FY 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) missed analyst estimates by 8.3%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Announcement • Apr 17
SonoScape Medical Corp., Annual General Meeting, May 13, 2026 SonoScape Medical Corp., Annual General Meeting, May 13, 2026, at 14:00 China Standard Time. Location: 1F, No. 368, Guangdian North Road, Guangming District, Shenzhen, Guangdong China Announcement • Mar 31
SonoScape Medical Corp. to Report Q1, 2026 Results on Apr 29, 2026 SonoScape Medical Corp. announced that they will report Q1, 2026 results on Apr 29, 2026 Announcement • Mar 18
SonoScape Medical Corp. (SZSE:300633) announces an Equity Buyback for CNY 200 million worth of its shares. SonoScape Medical Corp. (SZSE:300633) announces a share repurchase program. Under the program, the company will repurchase up to CNY 200 million worth of its A shares. The shares will be purchased at a price not exceeding CNY 40.32 per share. The purpose of program is cancellation of shares and reduce registered capital. The program will be funded from company's own funds or Self-Financing. The program will be valid for 12 months from the Company's Shareholders’ Approval Date. New Risk • Mar 02
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.4% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.2% net profit margin). Announcement • Dec 31
SonoScape Medical Corp. to Report Fiscal Year 2025 Results on Apr 17, 2026 SonoScape Medical Corp. announced that they will report fiscal year 2025 results on Apr 17, 2026 Buy Or Sell Opportunity • Dec 05
Now 20% overvalued Over the last 90 days, the stock has fallen 17% to CN¥26.94. The fair value is estimated to be CN¥22.37, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.0% over the last 3 years. Earnings per share has declined by 49%. Revenue is forecast to grow by 42% in 2 years. Earnings are forecast to grow by 614% in the next 2 years. Board Change • Dec 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. Independent Director Linghong Zhou was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Major Estimate Revision • Nov 04
Consensus EPS estimates fall by 14% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥2.24b to CN¥2.12b. EPS estimate also fell from CN¥0.697 per share to CN¥0.60 per share. Net income forecast to grow 413% next year vs 39% growth forecast for Medical Equipment industry in China. Consensus price target broadly unchanged at CN¥38.30. Share price fell 16% to CN¥28.63 over the past week. Reported Earnings • Oct 29
Third quarter 2025 earnings released: CN¥0.031 loss per share (vs CN¥0.14 loss in 3Q 2024) Third quarter 2025 results: CN¥0.031 loss per share (improved from CN¥0.14 loss in 3Q 2024). Revenue: CN¥495.0m (up 28% from 3Q 2024). Net loss: CN¥13.5m (loss narrowed 78% from 3Q 2024). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Announcement • Sep 30
SonoScape Medical Corp. to Report Q3, 2025 Results on Oct 29, 2025 SonoScape Medical Corp. announced that they will report Q3, 2025 results on Oct 29, 2025 Major Estimate Revision • Aug 28
Consensus EPS estimates fall by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥2.34b to CN¥2.25b. EPS estimate also fell from CN¥0.802 per share to CN¥0.713 per share. Net income forecast to grow 1,989% next year vs 38% growth forecast for Medical Equipment industry in China. Consensus price target broadly unchanged at CN¥40.66. Share price fell 8.1% to CN¥32.76 over the past week. Reported Earnings • Aug 22
Second quarter 2025 earnings released Second quarter 2025 results: Revenue: CN¥534.3m (flat on 2Q 2024). Net income: CN¥39.0m (down 45% from 2Q 2024). Profit margin: 7.3% (down from 13% in 2Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Announcement • Jul 02
SonoScape Medical Corp. to Report First Half, 2025 Results on Aug 22, 2025 SonoScape Medical Corp. announced that they will report first half, 2025 results on Aug 22, 2025 Buy Or Sell Opportunity • Jun 03
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 15% to CN¥33.34. The fair value is estimated to be CN¥27.50, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.4% over the last 3 years. Earnings per share has declined by 19%. Revenue is forecast to grow by 51% in 2 years. Earnings are forecast to grow by 957% in the next 2 years. Declared Dividend • May 24
Dividend reduced to CN¥0.10 Dividend of CN¥0.10 is 69% lower than last year. Ex-date: 29th May 2025 Payment date: 29th May 2025 Dividend yield will be 0.3%, which is lower than the industry average of 2.2%. Sustainability & Growth Dividend is covered by earnings (86% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 15% per year over the past 8 years. However, payments have been volatile during that time. EPS is expected to grow by 254% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Buy Or Sell Opportunity • May 13
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 8.6% to CN¥33.23. The fair value is estimated to be CN¥27.66, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.4% over the last 3 years. Earnings per share has declined by 19%. Revenue is forecast to grow by 52% in 2 years. Earnings are forecast to grow by 965% in the next 2 years. New Risk • Apr 26
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 51% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.6% net profit margin). Announcement • Apr 15
Sonoscape Medical Corp. Proposes Final Cash Dividend for the Year 2024 SonoScape Medical Corp. proposed final cash dividend/10 shares (tax included) of CNY 1.00000000 for the year 2024. Announcement • Apr 14
SonoScape Medical Corp., Annual General Meeting, May 14, 2025 SonoScape Medical Corp., Annual General Meeting, May 14, 2025, at 14:00 China Standard Time. Location: 1F, No. 368, Guangdian North Road, Guangming District, Shenzhen, Guangdong China Buy Or Sell Opportunity • Apr 12
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 12% to CN¥30.71. The fair value is estimated to be CN¥25.55, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has declined by 3.2%. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 48% per annum over the same time period. Announcement • Mar 31
SonoScape Medical Corp. to Report Q1, 2025 Results on Apr 26, 2025 SonoScape Medical Corp. announced that they will report Q1, 2025 results on Apr 26, 2025 Buy Or Sell Opportunity • Feb 12
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 18% to CN¥30.59. The fair value is estimated to be CN¥38.34, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 17%. Revenue is forecast to grow by 56% in 2 years. Earnings are forecast to grow by 197% in the next 2 years. Announcement • Dec 31
SonoScape Medical Corp. to Report Fiscal Year 2024 Results on Apr 12, 2025 SonoScape Medical Corp. announced that they will report fiscal year 2024 results on Apr 12, 2025 Buy Or Sell Opportunity • Dec 16
Now 21% undervalued Over the last 90 days, the stock has risen 24% to CN¥32.85. The fair value is estimated to be CN¥41.41, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 17%. Revenue is forecast to grow by 61% in 2 years. Earnings are forecast to grow by 202% in the next 2 years. Buy Or Sell Opportunity • Nov 20
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 19% to CN¥37.22. The fair value is estimated to be CN¥30.62, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 17%. Revenue is forecast to grow by 66% in 2 years. Earnings are forecast to grow by 211% in the next 2 years. Reported Earnings • Oct 26
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: CN¥0.14 loss per share (down from CN¥0.11 profit in 3Q 2023). Revenue: CN¥385.5m (down 9.2% from 3Q 2023). Net loss: CN¥61.6m (down 230% from profit in 3Q 2023). Revenue missed analyst estimates by 17%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Oct 25
Now 23% overvalued Over the last 90 days, the stock has fallen 1.6% to CN¥35.48. The fair value is estimated to be CN¥28.81, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 35%. Revenue is forecast to grow by 63% in 2 years. Earnings are forecast to grow by 118% in the next 2 years. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to CN¥31.90, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 19x in the Medical Equipment industry in China. Total loss to shareholders of 13% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥30.44 per share. Announcement • Sep 30
SonoScape Medical Corp. to Report Q3, 2024 Results on Oct 26, 2024 SonoScape Medical Corp. announced that they will report Q3, 2024 results on Oct 26, 2024 New Risk • Sep 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (91% cash payout ratio). Share price has been volatile over the past 3 months (7.5% average weekly change). Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to CN¥32.30, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 18x in the Medical Equipment industry in China. Total loss to shareholders of 19% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥30.25 per share. Reported Earnings • Aug 29
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: EPS: CN¥0.16 (down from CN¥0.32 in 2Q 2023). Revenue: CN¥533.4m (down 6.5% from 2Q 2023). Net income: CN¥70.4m (down 48% from 2Q 2023). Profit margin: 13% (down from 24% in 2Q 2023). The decrease in margin was primarily driven by lower revenue. Revenue missed analyst estimates by 8.2%. Earnings per share (EPS) also missed analyst estimates by 51%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Jul 12
Now 21% overvalued Over the last 90 days, the stock has fallen 8.0% to CN¥33.68. The fair value is estimated to be CN¥27.76, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings are also forecast to grow by 21% per annum over the same time period. Valuation Update With 7 Day Price Move • Jul 03
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥35.79, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 17x in the Medical Equipment industry in China. Total returns to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥27.50 per share. Announcement • Jun 29
SonoScape Medical Corp. to Report First Half, 2024 Results on Aug 29, 2024 SonoScape Medical Corp. announced that they will report first half, 2024 results on Aug 29, 2024 Declared Dividend • May 25
Dividend increased to CN¥0.32 Dividend of CN¥0.32 is 78% higher than last year. Ex-date: 29th May 2024 Payment date: 29th May 2024 Dividend yield will be 0.8%, which is lower than the industry average of 2.2%. Sustainability & Growth Dividend is covered by both earnings (33% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 38% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 102% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • May 25
SonoScape Medical Corp. 2023 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 29 May 2024 SonoScape Medical Corp. announced 2023 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 3.20000000. Record date: 28 May 2024. Ex-date: 29 May 2024. Payment date: 29 May 2024. Reported Earnings • Apr 27
First quarter 2024 earnings: EPS in line with expectations, revenues disappoint First quarter 2024 results: EPS: CN¥0.23 (down from CN¥0.32 in 1Q 2023). Revenue: CN¥479.3m (up 1.3% from 1Q 2023). Net income: CN¥100.2m (down 28% from 1Q 2023). Profit margin: 21% (down from 29% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 9.7%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Price Target Changed • Apr 23
Price target decreased by 7.8% to CN¥50.15 Down from CN¥54.40, the current price target is an average from 6 analysts. New target price is 27% above last closing price of CN¥39.40. Stock is down 25% over the past year. The company is forecast to post earnings per share of CN¥1.36 for next year compared to CN¥1.06 last year. Reported Earnings • Apr 14
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: EPS: CN¥1.06 (up from CN¥0.86 in FY 2022). Revenue: CN¥2.12b (up 20% from FY 2022). Net income: CN¥454.4m (up 23% from FY 2022). Profit margin: 21% (in line with FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 3.0%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Announcement • Mar 30
SonoScape Medical Corp. to Report Q1, 2024 Results on Apr 27, 2024 SonoScape Medical Corp. announced that they will report Q1, 2024 results on Apr 27, 2024 Board Change • Feb 11
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Independent Director Linghong Zhou was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥39.74, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 21x in the Medical Equipment industry in China. Total returns to shareholders of 53% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥67.09 per share. Announcement • Feb 06
SonoScape Medical Corp. Approves Board Elections SonoScape Medical Corp. announced that at its EGM held on 2 February 2024, approved election of Wu Kunxiang, Huang Yibo and Zhou Wenping as non-independent directors, Xu Shunzhi as independent director of the company. Announcement • Dec 29
SonoScape Medical Corp. to Report Fiscal Year 2023 Results on Apr 12, 2024 SonoScape Medical Corp. announced that they will report fiscal year 2023 results on Apr 12, 2024 Price Target Changed • Dec 27
Price target decreased by 8.0% to CN¥57.34 Down from CN¥62.30, the current price target is an average from 6 analysts. New target price is 21% above last closing price of CN¥47.47. Stock is down 13% over the past year. The company is forecast to post earnings per share of CN¥1.11 for next year compared to CN¥0.86 last year. Buying Opportunity • Dec 06
Now 21% undervalued Over the last 90 days, the stock is up 17%. The fair value is estimated to be CN¥63.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has grown by 74%. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings is also forecast to grow by 20% per annum over the same time period. Announcement • Nov 09
SonoScape Medical Corp. (SZSE:300633) announces an Equity Buyback for CNY 120 million worth of its shares. SonoScape Medical Corp. (SZSE:300633) announces a share repurchase program. Under the program, the company will repurchase up to CNY 120 million worth of its A shares. The shares will be purchased at a price not exceeding CNY 68 per share. The repurchased shares will be used for employee stock ownership plans or equity incentive plans. The program will be funded from company's own funds or self-raised funds. The program will be valid for 12 months. Reported Earnings • Oct 26
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Third quarter 2023 results: EPS: CN¥0.11 (down from CN¥0.17 in 3Q 2022). Revenue: CN¥424.5m (up 2.1% from 3Q 2022). Net income: CN¥47.6m (down 33% from 3Q 2022). Profit margin: 11% (down from 17% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 61%. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth. Price Target Changed • Sep 19
Price target decreased by 7.4% to CN¥62.43 Down from CN¥67.40, the current price target is an average from 6 analysts. New target price is 30% above last closing price of CN¥48.08. Stock is up 20% over the past year. The company is forecast to post earnings per share of CN¥1.17 for next year compared to CN¥0.86 last year. Reported Earnings • Aug 23
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2023 results: EPS: CN¥0.32 (up from CN¥0.29 in 2Q 2022). Revenue: CN¥570.3m (up 23% from 2Q 2022). Net income: CN¥134.6m (up 8.7% from 2Q 2022). Profit margin: 24% (down from 27% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 4.5%. Earnings per share (EPS) exceeded analyst estimates by 13%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Announcement • Jul 01
SonoScape Medical Corp. to Report Q2, 2023 Results on Aug 23, 2023 SonoScape Medical Corp. announced that they will report Q2, 2023 results on Aug 23, 2023 Announcement • Jun 03
SonoScape Medical Corp. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date: 08 June 2023 SonoScape Medical Corp. announced 2022 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 1.80000000, Record date: 07 June 2023, Ex-date: 08 June 2023 and Payment date: 08 June 2023. Reported Earnings • Apr 12
Full year 2022 earnings: EPS exceeds analyst expectations Full year 2022 results: EPS: CN¥0.86 (up from CN¥0.62 in FY 2021). Revenue: CN¥1.76b (up 22% from FY 2021). Net income: CN¥369.8m (up 50% from FY 2021). Profit margin: 21% (up from 17% in FY 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.8%. Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Dec 29
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥54.83, the stock trades at a forward P/E ratio of 54x. Average forward P/E is 23x in the Medical Equipment industry in China. Total returns to shareholders of 127% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥23.10 per share. Price Target Changed • Nov 16
Price target increased to CN¥71.16 Up from CN¥48.40, the current price target is provided by 1 analyst. New target price is 38% above last closing price of CN¥51.70. Stock is up 69% over the past year. The company is forecast to post earnings per share of CN¥0.77 for next year compared to CN¥0.62 last year. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Chairman of the Supervisory Board Alan Chen was the last director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Oct 26
Third quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.076 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.17 (up from CN¥0.076 in 3Q 2021). Revenue: CN¥415.8m (up 40% from 3Q 2021). Net income: CN¥70.6m (up 133% from 3Q 2021). Profit margin: 17% (up from 10% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 14
Investor sentiment improved over the past week After last week's 26% share price gain to CN¥58.44, the stock trades at a forward P/E ratio of 67x. Average forward P/E is 23x in the Medical Equipment industry in China. Total returns to shareholders of 149% over the past three years. Valuation Update With 7 Day Price Move • Sep 29
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥46.30, the stock trades at a forward P/E ratio of 54x. Average forward P/E is 22x in the Medical Equipment industry in China. Total returns to shareholders of 81% over the past three years. Reported Earnings • Aug 24
Second quarter 2022 earnings released: EPS: CN¥0.29 (vs CN¥0.18 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.29 (up from CN¥0.18 in 2Q 2021). Revenue: CN¥464.9m (up 29% from 2Q 2021). Net income: CN¥123.8m (up 70% from 2Q 2021). Profit margin: 27% (up from 20% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 24%, compared to a 26% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jul 11
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥37.48, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 23x in the Medical Equipment industry in China. Total returns to shareholders of 40% over the past three years. Announcement • Jul 09
Sonoscape Medical Corp. Announces Final Dividend on Share A for 2021, Payable on July 15, 2022 SonoScape Medical Corp. announced Cash dividend/10 shares (tax included): CNY 1.25000000 on share A for 2021. Record date: 14 July 2022, Ex-date: 15 July 2022 and Payment date: 15 July 2022. Announcement • May 21
SonoScape Medical Corp. Approves 2021 Profit Distribution Plan SonoScape Medical Corp. approved 2021 profit distribution plan. The detailed profit distribution plan are as follows: 1) Cash dividend/10 shares (tax included): CNY 1.25000000. Announcement • Apr 28
SonoScape Medical Corp. Proposes Final Cash Dividend for 2021 SonoScape Medical Corp. proposed final cash dividend per 10 shares (tax included) of CNY 1.25000000 for 2021. Reported Earnings • Apr 27
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2022 results: EPS: CN¥0.12 (up from CN¥0.09 in 1Q 2021). Revenue: CN¥370.6m (up 32% from 1Q 2021). Net income: CN¥51.1m (up 41% from 1Q 2021). Profit margin: 14% (up from 13% in 1Q 2021). Revenue missed analyst estimates by 6.1%. Earnings per share (EPS) exceeded analyst estimates by 10%. Over the next year, revenue is forecast to grow 28%, compared to a 25% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 6% per year. Announcement • Apr 26
SonoScape S-Fetus 4.0 Release to Simplify Sonography Process SonoScape Medical Corp. announced the release of S-Fetus 4.0, the latest software upgrade of the company's ultrasound product offering. This technical breakthrough marks S-Fetus 4.0 as the globally first smart obstetric screening technology based on deep learning. Leveraging the deep learning techniques, the S-Fetus 4.0 Obstetric Screening Assistant allows doctors to automatically acquire standard planes and measure fetal biometry with fast performance and accuracy. Without the need for manually repetitive operation of the device, the system was designed with one-click simple touch to streamline the sonogram pocess and improve scanning efficiency. To improve service capability, SonoScape applied this newly upgrade to a variety of high-end ultrasound equipment. The S-Fetus 4.0 is going to run on SonoScape S60, P60, P60 Exp, S50 Elite, P50 Elite and P40 Elite, both in the North America and ROW Region. Announcement • Apr 16
SonoScape Medical Corp. Receives FDA 510(k) Clearance for HD-550 Endoscopy system On April 15th, SonoScape Medical Corp. announced that the U.S. Food and Drug Administration (FDA) has approved its video endoscopy system HD-550 for gastrointestinal diagnosis, setting up a major milestone on SonoScape's Endoscopic product roadmap. Paired with a 4-LED light source, which supports 1080P high definition, the HD-550 endoscopy system enables multi-spectrum and multi-mode. Adding to the high-performing white-light mode, its chromoendoscopy SFI (Spectral Focused Imaging) and VIST (Versatile Intelligent Staining Technology) light modes enhance vascular and mucosal color contrast. As a result, more details in the GI tract can be revealed, which may help doctors in detection, demarcation, and characterization of the lesions. Included in the clearance are the 550 series videoscopes, whose maneuverability has been endorsed by top endoscopists around the world. The HD-550 endoscopy system has been available outside of the USA since 2019. By 2021, HD550's top-of-the-line features and quality combined with its versatility saw it installed in close to 40 countries around the world and has made SonoScape the third best-selling brand in China. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.076 (vs CN¥0.004 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥297.4m (up 32% from 3Q 2020). Net income: CN¥30.3m (up CN¥28.7m from 3Q 2020). Profit margin: 10% (up from 0.7% in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 18
Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.085 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥360.9m (up 43% from 2Q 2020). Net income: CN¥72.9m (up 118% from 2Q 2020). Profit margin: 20% (up from 13% in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance. Announcement • Jul 03
SonoScape Obtains CE-Mark for Its Linear Array Echoendoscope EG-UC5T On April 30th, SonoScape received the CE-marking, the product's "Passport to Europe", for its linear-array echoendoscope EG-UC5T. This further expands SonoScape's endoscopic ultrasound (EUS) portfolio in the international market. Reaping the benefits of decades of ultrasound technology know-how, SonoScape's EUS product line officially debuted in September 2019, when its 360° radial-array echoendoscope EG-UR5 obtained the CE Marking, leaping to the 4th company in the world to master the core technology of EUS. EG-UC5T is characterised by its large, 4.0-mm instrument channel and its short rigid distal end, pushing the boundaries of therapeutic excellence. With the arrival of the linear-array echoendoscope EG-UC5T, SonoScape users are not only able to perform the adequate tissue sampling, but also various therapeutic interventional endoscopic procedures under the sonographic guidance. This is a true "best of the two worlds", a golden key to reveal what's behind the GI tract mucosa and to unlock the growing possibilities of advanced endoscopy. Price Target Changed • May 01
Price target increased to CN¥30.86 Up from CN¥27.27, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of CN¥30.13. Stock is up 3.1% over the past year. Announcement • Apr 27
Sonoscape Medical Corp. Proposes Final Cash Dividend for 2020 SonoScape Medical Corp. proposed final cash dividend (tax included) of CNY 0.000000 per ten shares for 2020. Reported Earnings • Apr 25
First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.02 loss in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥281.8m (up 20% from 1Q 2020). Net income: CN¥36.1m (up CN¥44.4m from 1Q 2020). Profit margin: 13% (up from net loss in 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance. Is New 90 Day High Low • Jan 28
New 90-day low: CN¥20.36 The company is down 21% from its price of CN¥25.79 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥1.90 per share.